Clinical Trial Update: Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates low-dose ATG plus low-dose PTCy as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• ATG (anti-thymocyte globulin)
• PTCy (post-transplant cyclophosphamide)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Graft-versus-host-disease, Prophylaxis | Phase 2 | Status: UNKNOWN